CoChat
Sign Up
Cited by 174Amyotrophic Lateral Sclerosis ResearchAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort

Open access
Gijselinck, Ilse, Van Mossevelde, Sara, van der Zee, Julie, Sieben, Anne, Philtjens, Stéphanie, Heeman, Bavo, Engelborghs, Sebastiaan, Vandenbulcke, Mathieu, De Baets, Greet, Bäumer, Veerle, Cuijt, Ivy, Van den Broeck, Marleen, Peeters, Karin, Mattheijssens, Maria, Rousseau, Frederic, Vandenberghe, Rik, De Jonghe, Peter, Cras, Patrick, De Deyn, Peter P., Martin, Jean-Jacques, Cruts, Marc, Van Broeckhoven, Christine, BELNEU Consortium, Nuytten, Dirk, Van Langenhove, Tim, Smets, Katrien, Baets, Jonathan, Robberecht, Wim, Van Damme, Philip, De Bleecker, Jan, Santens, Patrick, Dermaut, Bart, Deryck, Olivier, Bergmans, Bruno, Delbeck, Jean, Versijpt, Jan, Michotte, Alex, Willems, Christiana, Ivanoiu, Adrian, Salmon, Eric·2015·Neurology
DOI 10.1212/wnl.0000000000002220PMC PMC4691687
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE: To assess the genetic contribution of TBK1, a gene implicated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and FTD-ALS, in Belgian FTD and ALS patient cohorts containing a significant part of genetically unresolved patients. METHODS: We sequenced TBK1 in a hospital-based cohort of 482 unrelated patients with FTD and FTD-ALS and 147 patients with ALS and an extended Belgian FTD-ALS family DR158. We followed up mutation carriers by segregation studies, transcript and protein expression analysis, and immunohistochemistry. RESULTS: We identified 11 patients carrying a loss-of-function (LOF) mutation resulting in an overall mutation frequency of 1.7% (11/629), 1.1% in patients with FTD (5/460), 3.4% in patients with ALS (5/147), and 4.5% in patients with FTD-ALS (1/22). We found 1 LOF mutation, p.Glu643del, in 6 unrelated patients segregating with disease in family DR158. Of 2 mutation carriers, brain and spinal cord was characterized by TDP-43-positive pathology. The LOF mutations including the p.Glu643del mutation led to loss of transcript or protein in blood and brain. CONCLUSIONS: TBK1 LOF mutations are the third most frequent cause of clinical FTD in the Belgian clinically based patient cohort, after C9orf72 and GRN, and the second most common cause of clinical ALS after C9orf72. These findings reinforce that FTD and ALS belong to the same disease continuum.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000002220

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Pedigrees show segregation and disease haplotype sharing in patients and families with the TBK1 mutation p.Glu643del To protect the privacy of the participants, we masked the sex of each person, scrambled the pedigree of family DR158, and did not specify the number of at-risk individuals tested shown in the white diamonds. The index patient is indicated with an arrow. Filled symbols represent patients, with their age at onset (AAO) in years below their symbol. Age at death (AAD) is shown for individuals who died in old age without symptoms. In family DR663, 3 of the 4 children also carry a repeat expansion mutation in C9orf72, 2 affected (I-1 and II-2) and 1 asymptomatic (II-4), for whom the age at last examination (AALE) is given. An asterisk identifies the family members for whom genomic DNA was available. The Glu643del mutation is shown as “–.” The 5 polymorphic markers, including the TBK1-(GT)n repeat polymorphism located 400 kb upstream of TBK1, are indicated at the left and flank the TBK1 mutation p.Glu643del at both sites. Genotypes of additional polymorphic markers can be found in table e-3. The 3 different disease haplotypes are shown with colored bars: green haplotype of at least 7.5 Mb, purple haplotype of at least 8.7 Mb, and orange haplotype of at least 3.0 Mb. Haplotypes based on segregation data are indicated in regular font, those based on allele sharing are in italics, and those that were inferred are between brackets. ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia.
Figure 1 Pedigrees show segregation and disease haplotype sharing in patients and families with the TBK1 mutation p.Glu643del To protect the privacy of the participants, we masked the sex of each person, scrambled the pedigree of family DR158, and did not specify the number of at-risk individuals tested shown in the white diamonds. The index patient is indicated with an arrow. Filled symbols represent patients, with their age at onset (AAO) in years below their symbol. Age at death (AAD) is shown for individuals who died in old age without symptoms. In family DR663, 3 of the 4 children also carry a repeat expansion mutation in C9orf72, 2 affected (I-1 and II-2) and 1 asymptomatic (II-4), for whom the age at last examination (AALE) is given. An asterisk identifies the family members for whom genomic DNA was available. The Glu643del mutation is shown as “–.” The 5 polymorphic markers, including the TBK1-(GT)n repeat polymorphism located 400 kb upstream of TBK1, are indicated at the left and flank the TBK1 mutation p.Glu643del at both sites. Genotypes of additional polymorphic markers can be found in table e-3. The 3 different disease haplotypes are shown with colored bars: green haplotype of at least 7.5 Mb, purple haplotype of at least 8.7 Mb, and orange haplotype of at least 3.0 Mb. Haplotypes based on segregation data are indicated in regular font, those based on allele sharing are in italics, and those that were inferred are between brackets. ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia.CC BY-NC-ND · PubMed Central
Figure 2 Transcript analysis of TBK1 loss-of-function mutations Quantitative PCR quantification of TBK1 transcripts from lymphoblast cells (A) and frontal cortex (B) of LOF mutation carriers (blue bars) compared to control persons without mutation (black bars) normalized to different housekeeping genes. Five unrelated p.Glu643del mutation carriers were included. Error bars represent the SD. Below the chart is indicated if cells were treated (+, dark blue bars) or not treated (−, light blue bars) with cycloheximide (CHX), a protein synthesis inhibitor. Sequence traces are obtained by real-time PCR from the lymphoblast cells of the p.Ser398Profs*11 mutation carrier treated or not treated with CHX using primers in exon 6 and exon 21. (C) Real-time PCR with primers in exon 6 and 10 of cDNA of brain of the p.Gly272_Thr331del mutation carriers is shown on agarose gel, with the respective sequence traces from the aberrant transcripts.
Figure 2 Transcript analysis of TBK1 loss-of-function mutations Quantitative PCR quantification of TBK1 transcripts from lymphoblast cells (A) and frontal cortex (B) of LOF mutation carriers (blue bars) compared to control persons without mutation (black bars) normalized to different housekeeping genes. Five unrelated p.Glu643del mutation carriers were included. Error bars represent the SD. Below the chart is indicated if cells were treated (+, dark blue bars) or not treated (−, light blue bars) with cycloheximide (CHX), a protein synthesis inhibitor. Sequence traces are obtained by real-time PCR from the lymphoblast cells of the p.Ser398Profs*11 mutation carrier treated or not treated with CHX using primers in exon 6 and exon 21. (C) Real-time PCR with primers in exon 6 and 10 of cDNA of brain of the p.Gly272_Thr331del mutation carriers is shown on agarose gel, with the respective sequence traces from the aberrant transcripts.CC BY-NC-ND · PubMed Central
Figure 3 Protein analysis of TBK1 loss-of-function mutations Western blot analysis of protein extracts from lymphoblast cells (A) and frontal cortex (B) of loss-of-function (LOF) mutation carriers compared to control persons without mutation. Of the p.Glu643del mutation, 5 unrelated index patients were included. The upper band represents TBK1 (84 kDa) and the lower band the housekeeping protein GAPDH (37 kDa). The graphs below (C) show the quantification in control samples (black) and patient samples (blue) of the TBK1 signal normalized to the signal of GAPDH. Error bars represent the SD; ** indicates a significant p value of <0.01 compared to controls.
Figure 3 Protein analysis of TBK1 loss-of-function mutations Western blot analysis of protein extracts from lymphoblast cells (A) and frontal cortex (B) of loss-of-function (LOF) mutation carriers compared to control persons without mutation. Of the p.Glu643del mutation, 5 unrelated index patients were included. The upper band represents TBK1 (84 kDa) and the lower band the housekeeping protein GAPDH (37 kDa). The graphs below (C) show the quantification in control samples (black) and patient samples (blue) of the TBK1 signal normalized to the signal of GAPDH. Error bars represent the SD; ** indicates a significant p value of <0.01 compared to controls.CC BY-NC-ND · PubMed Central
Figure 4 TDP-43, p62, and TBK1 immunohistochemistry Immunohistochemistry of frontal cortex (A, D, G) and hippocampus (B, E, H) of 1 patient with frontotemporal lobar degeneration with the p.Gly272_Thr331del mutation (DR189) and spinal cord (C, F, I) of 1 patient with amyotrophic lateral sclerosis (ALS) with the p.Ser518Leufs*32 mutation (DR1124) compared to a control individual without mutation (J–L). In frontotemporal dementia patient DR189, a mild neuronal loss of the frontal cortices and to a lesser extent of the temporal neocortex and the hippocampus was shown. A moderate amount of TDP-43 and p62 neuronal cytoplasmic inclusions (NCI) (arrows) and short dystrophic neurites, but no intraneuronal intranuclear inclusions, were found throughout all layers of the frontal (A, D) and temporal neocortices, in the dentate gyrus of the hippocampus (B, E), the parahippocampal transentorhinal cortex, the neostriatum, and the pallidum, but not in the cerebellum. In ALS patient DR1124, no explicit cortical abnormalities were present, but pathologic signs of lower and upper motor neuron disease were apparent. Severe demyelination of the pyramidal tract in mesencephalon, pons, medulla oblongata, and the entire spinal cord and severe neuronal loss in the hypoglossal nucleus, as well as in the ventral horns of the cervical and thoracic spinal cord, were observed. The TDP-43-positive (C) and p62-positive (F) NCI were mainly restricted to the hypoglossal nucleus and the ventral horn neurons of cervical and thoraco-lumbar spinal cord (arrows). Cytoplasmic TBK1 immunoreactivity (arrows) in cortical neurons of the frontal cortex (G, J), in the dentate gyrus of the hippocampus (H, K), and in the cervical ventral horn neurons (I, L) showed no differences between patients and controls. The TDP-43-positive inclusions were not stained with TBK1.
Figure 4 TDP-43, p62, and TBK1 immunohistochemistry Immunohistochemistry of frontal cortex (A, D, G) and hippocampus (B, E, H) of 1 patient with frontotemporal lobar degeneration with the p.Gly272_Thr331del mutation (DR189) and spinal cord (C, F, I) of 1 patient with amyotrophic lateral sclerosis (ALS) with the p.Ser518Leufs*32 mutation (DR1124) compared to a control individual without mutation (J–L). In frontotemporal dementia patient DR189, a mild neuronal loss of the frontal cortices and to a lesser extent of the temporal neocortex and the hippocampus was shown. A moderate amount of TDP-43 and p62 neuronal cytoplasmic inclusions (NCI) (arrows) and short dystrophic neurites, but no intraneuronal intranuclear inclusions, were found throughout all layers of the frontal (A, D) and temporal neocortices, in the dentate gyrus of the hippocampus (B, E), the parahippocampal transentorhinal cortex, the neostriatum, and the pallidum, but not in the cerebellum. In ALS patient DR1124, no explicit cortical abnormalities were present, but pathologic signs of lower and upper motor neuron disease were apparent. Severe demyelination of the pyramidal tract in mesencephalon, pons, medulla oblongata, and the entire spinal cord and severe neuronal loss in the hypoglossal nucleus, as well as in the ventral horns of the cervical and thoracic spinal cord, were observed. The TDP-43-positive (C) and p62-positive (F) NCI were mainly restricted to the hypoglossal nucleus and the ventral horn neurons of cervical and thoraco-lumbar spinal cord (arrows). Cytoplasmic TBK1 immunoreactivity (arrows) in cortical neurons of the frontal cortex (G, J), in the dentate gyrus of the hippocampus (H, K), and in the cervical ventral horn neurons (I, L) showed no differences between patients and controls. The TDP-43-positive inclusions were not stained with TBK1.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Gijselinck, I., Van Mossevelde, S., van der Zee, J., Sieben, A., Philtjens, S., Heeman, B., Engelborghs, S., Vandenbulcke, M., De Baets, G., Bäumer, V., Cuijt, I., Van den Broeck, M., Peeters, K., Mattheijssens, M., Rousseau, F., Vandenberghe, R., De Jonghe, P., Cras, P., De Deyn, P. P., Martin, J.-J., Cruts, M., Van Broeckhoven, C., BELNEU Consortium, Nuytten, D., Van Langenhove, T., Smets, K., Baets, J., Robberecht, W., Van Damme, P., De Bleecker, J., Santens, P., Dermaut, B., Deryck, O., Bergmans, B., Delbeck, J., Versijpt, J., Michotte, A., Willems, C., Ivanoiu, A., & Salmon, E.
Affiliations
  • University Medical Center Groningen (NL)
  • From the Department of Molecular Genetics (I.G., S.V.M., J.v.d.Z., A.S., S.P., B.H., V.B., I.C., M.V.d.B., K.P., M.M., P.D.J., M.C., C.V.B.), VIB, Antwerp; Institute Born-Bunge (I.G., S.V.M., J.v.d.Z., A.S., S.P., B.H., S.E., V.B., I.C., M.V.d.B., K.P., M.M., P.D.J., P.C., P.P.D.D., J.-J.M., M.C., C.V.B.), University of Antwerp; the Department of Neurology (A.S.), University Hospital Ghent and University of Ghent; the Department of Neurology and Memory Clinic (S.E., P.P.D.D.), Hospital Network...
Corresponding author
Cruts, Marc
ORCID
Venue
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2015-12-15
Volume
85
Issue
24
Pages
2116-2125
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
DOI
10.1212/wnl.0000000000002220
PMC
PMC4691687
OpenAlex
W2210071362
Cited by
174
References
42
Citations by year
2026: 4 · 2025: 8 · 2024: 10 · 2023: 11 · 2022: 13 · 2021: 24 · 2020: 22 · 2019: 19 · 2018: 23 · 2017: 19 · 2016: 18 · 2015: 3
FWCI
14.81
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Neurology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
  • Lirias (submittedVersion, other-oa)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
  • Digital Access to Libraries (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc-nd)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders
  • MetLife Foundation
  • Belgian Federal Science Policy Office
  • Fonds Wetenschappelijk Onderzoek
  • Universiteit Antwerpen
  • Vlaamse regering
  • Instituut Born-Bunge
  • Fondation pour la Recherche sur Alzheimer
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
TBK1, frontotemporal dementia, amyotrophic lateral sclerosis, loss-of-function mutations, TDP-43 pathology, genetic susceptibility, family segregation
MeSH terms
Adult, Aged, Aged, 80 and over, Belgium, Female, Humans, Male, Middle Aged, Mutation, Pedigree, Cohort Studies, Protein Serine-Threonine Kinases, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review